Close Menu
    New Delhi BulletinNew Delhi Bulletin
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    New Delhi BulletinNew Delhi Bulletin
    Home » MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
    PR Newswire

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    February 14, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

    SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ — MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world’s first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

    MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

    Revolutionizing Collagen Filler Technology

    SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body’s natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

    Why Recombinant Human Collagen?

    Highly Body-Friendly: SKINCOLLA’s recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

    With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

    Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

    Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it’s suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

    Cutting-Edge Technology for Long-Lasting Results

    The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

    Who Can Benefit from SKINCOLLA?

    SKINCOLLA is ideal for individuals seeking:

    Natural, subtle results without the “overdone” look often associated with traditional fillers.

    Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

    Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

    Indications for SKINCOLLA

    Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow’s feet, and marionette lines.

    Eyes: Dark circle reduction, eye wrinkles, and puffiness.

    Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

    For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact sales@maypharm.co.kr.

    Photo – https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/maypharm-co-ltd-launches-skincolla-the-worlds-first-recombinant-human-collagen-filler-for-superior-skin-rejuvenation-302376946.html


    Related Posts

    ThreatBook Launches Best-of-Breed Advanced Threat Intelligence Solution

    September 29, 2025

    2025 Yidan Prize spotlights changemakers advancing complex systems literacy and multilingual education

    September 29, 2025

    Seekapa Introduces an Updated Platform Interface for Smoother Trading

    September 22, 2025

    vivo Shines with Dual Honors: No.34 on BrandZ Top 100 and "2025 Kantar BrandZ Inspirational Star of Innovation" Award

    September 22, 2025

    Italy, Ecomondo 2025 is ready to go with over 100 events scheduled

    September 22, 2025

    Alfaisal University Secures LUYTEN 3D Printer to Advance Innovation in Architecture and Sustainability

    September 22, 2025
    Latest News

    Shanxi coal mine explosion kills 82 workers

    May 25, 2026

    AI chip demand lifts Singapore Q1 GDP growth to 6%

    May 25, 2026

    Measles outbreak in Bangladesh passes 60,000 cases

    May 23, 2026

    PM Modi and Meloni spotlight deepening India-Italy ties

    May 21, 2026

    UAE and Germany review strategic ties in Berlin

    May 21, 2026

    Japan and South Korea launch energy security framework

    May 20, 2026

    South Korea launches $665.5 million industrial growth fund

    May 20, 2026

    Etihad expands Paris route with double daily A380 flights

    May 20, 2026

    GME posts strongest trading week in two decades

    May 19, 2026
    © 2026 New Delhi Bulletin | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.